Study guide
13.3 Pharmacotherapy Research for Stimulant Use Disorder
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
13.3 Pharmacotherapy Research for Stimulant Use Disorder
Key Takeaways Explain This Topic AI
No medication is FDA-approved for cocaine or methamphetamine use disorder, so every pharmacologic option is off-label and must be presented to the patient as such.
The ADAPT-2 trial produced a 13.6% response rate with extended-release injectable naltrexone plus bupropion versus 2.5% with placebo, an 11.1 percentage point difference and a number needed to treat of about 9.
Mirtazapine reduced methamphetamine use in randomized trials of men who have sex with men, with the added benefit of treating the insomnia that dominates early abstinence.
Topiramate and long-acting amphetamine agonist therapy have the most supportive evidence for cocaine use disorder, particularly in patients who achieve initial abstinence.
Any off-label pharmacotherapy for stimulant use disorder must be layered onto contingency management, which remains the intervention with the largest effect size.
Last updated: September 2026
13.3 Pharmacotherapy Research for Stimulant Use Disorder
Quick Answer: No FDA-approved medication exists for cocaine or methamphetamine use disorder. The strongest randomized evidence is ADAPT-2 (extended-release injectable naltrexone 380 mg every 3 weeks plus extended-release bupropion titrated to 450 mg daily): 13.6% response versus 2.5% placebo , an absolute difference of 11.1 percentage points and NNT of about 9 . Other agents with supportive randomized data include mirtazapine (methamphetamine), topiramate (cocaine, especially after initial abstinence), and prescription psychostimulant agonist therapy with long-acting mixed amphetamine salts or methylphenidate. All are off-label and all are adjuncts to contingency management.
1. Why the Pharmacology Is Hard
Opioid and alcohol pharmacotherapy works because there is a receptor to occupy or an enzyme to block. Stimulants act on transporters, and the downstream injury is a network problem: depleted dopamine tone, dysregulated glutamate signaling from prefrontal cortex to accumbens, and impaired executive control. There is no single target whose blockade abolishes reinforcement without abolishing normal motivation. This is worth explaining to patients who ask, "Why is there a pill for heroin and not for meth?"
2. Agents With Randomized Evidence
Agent / regimen Target Evidence Practical notes
XR-naltrexone 380 mg IM q3 weeks + bupropion XL to 450 mg/day Methamphetamine ADAPT-2 (NEJM 2021): 13.6% vs 2.5% response; NNT about 9 Requires 7 to 10 opioid-free days before naltrexone; bupropion lowers seizure threshold; screen for eating disorder and seizure history
Mirtazapine 30 mg at bedtime Methamphetamine (studied in men who have sex with men) Two randomized trials showed reduced methamphetamine-positive urine samples Also treats early-abstinence insomnia and appetite loss; sedation and weight gain are the limiting effects
Topiramate titrated to 200–300 mg/day Cocaine Randomized data favor benefit, strongest in patients who achieve initial abstinence Cognitive dulling, paresthesias, metabolic acidosis, nephrolithiasis, weight loss; teratogenic
Long-acting prescription psychostimulants (mixed amphetamine salts ER, methylphenidate ER) Cocaine and methamphetamine, especially with comorbid ADHD Agonist-substitution trials show reduced use at higher doses Diversion and cardiovascular risk require structured monitoring, PDMP review and limited supply
Bupropion alone Methamphetamine Benefit limited to lower-frequency users in earlier trials; ADAPT-2 tested it only in combination Not a stand-alone answer for daily heavy use
Naltrexone alone Amphetamine (Swedish trials) Modest reduction in amphetamine use Weaker evidence than the combination
Modafinil Cocaine Mixed; possible benefit in patients without comorbid alcohol use disorder Not first line
Disulfiram Cocaine Older trials suggested benefit via dopamine beta-hydroxylase inhibition; later trials inconsistent Not recommended as routine care
Agents to know as negatives: antipsychotics do not treat stimulant use disorder and worsen dysphoria and adherence; SSRIs have repeatedly failed; and there is no evidence supporting "detox protocols" with scheduled benzodiazepines for stimulant withdrawal.
3. Interpreting ADAPT-2 for Patients and Colleagues
ADAPT-2 randomized 403 adults with moderate-to-severe methamphetamine use disorder across NIDA Clinical Trials Network sites in a two-stage, double-blind, placebo-controlled design. Response required at least 3 of 4 methamphetamine-negative urine samples during the final two weeks of each stage.
Response: 13.6% active versus 2.5% placebo; difference 11.1 percentage points (Wald z = 4.53).
NNT = 1 divided by 0.111, which is about 9.
Two honest framings the APRN should be able to deliver:
To a colleague who dismisses it: "An NNT of 9 for a condition with no approved therapy is meaningful. We accept comparable numbers in cardiology."
To a patient: "Most people in that study did not reach the strict abstinence endpoint. What the medication reliably does for some people is take the edge off craving so the rest of the plan has room to work. It is not the plan by itself."
4. Prescribing Safely Off-Label
Document the off-label discussion. Record that the patient was told the agent is not FDA-approved for this indication, the magnitude of expected benefit, the alternatives including contingency management, and the specific risks.
Screen before naltrexone. Confirm 7 to 10 opioid-free days (14 for methadone) and check liver function. In the fentanyl era, confirm the opioid-free interval carefully — patients frequently underestimate residual depot fentanyl.
Screen before bupropion. Absolute contraindications are seizure disorder, current or prior bulimia or anorexia nervosa, abrupt discontinuation of alcohol or sedatives, and MAOI use within 14 days.
Screen before topiramate. Pregnancy status and contraception plan, renal stones, and baseline cognitive function.
Set a stop rule. Define in advance what constitutes non-response (for example, no reduction in use frequency and no reduction in craving at 12 weeks) and discontinue rather than accumulating ineffective medications. The 2025 practice analysis added a specific activity statement for this: "Evaluates the need for continuation or discontinuation of pharmacologic agents."